NCT02027935View on ClinicalTrials.gov

CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

January 22, 2015

Primary Completion Date

April 12, 2024

Study Completion Date

April 12, 2024

Conditions
Metastatic MelanomaStage IV Cutaneous Melanoma AJCC v6 and v7
Interventions
BIOLOGICAL

Aldesleukin

Given SC

BIOLOGICAL

Autologous CD8+ Melanoma Specific T Cells

Given IV

DRUG

Cyclophosphamide

Given IV

BIOLOGICAL

Ipilimumab

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT02027935 - CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma | Biotech Hunter | Biotech Hunter